Roche Holding AG (SWX:RO)
Switzerland
· Delayed Price · Currency is CHF 321.00
+4.80 (1.52%)
Mar 3, 2025, 5:31 PM CET
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
604.32K CHF
Profits / Employee
80.17K CHF
Market Cap
239.80B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Roche Holding AG | 103,249 |
| Novartis AG | 75,883 |
| Alcon | 25,599 |
| Lonza Group AG | 18,686 |
| Galderma Group AG | 6,545 |
| Straumann Holding AG | 11,815 |
| Sandoz Group AG | 22,633 |
| Sonova Holding AG | 18,151 |
Roche Holding AG News
- 4 days ago - Immune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with Roche - Business Wire
- 4 days ago - Roche: Sustainable Sales Growth, Margin Leverage, And Supportive Late-Stage Pipeline - Seeking Alpha
- 5 days ago - Roche: Balanced Between Catalysts And Headwinds - Seeking Alpha
- 11 days ago - Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology - GlobeNewsWire
- 12 days ago - Roche goes beyond diagnostics innovation and builds partnerships for proactive healthcare - South China Morning Post
- 13 days ago - Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche - Business Wire
- 18 days ago - Roche upgraded by UBS to buy on growth outlook - Seeking Alpha
- 19 days ago - FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) - GlobeNewsWire